Effect of the second-generation vascular disrupting agent OXI4503 on tumor vascularity

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 4090-4094

  Salmon, Howard W ^a,b   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; HOE 33342; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERFUSION; PRIORITY JOURNAL; SARCOMA; STAINING; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANIMALS; CELL SURVIVAL; DIPHOSPHATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; INJECTIONS, INTRAPERITONEAL; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA, EXPERIMENTAL; STILBENES; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746091695     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0163     Document Type: Article

References (33)

1. Denekamp J, Hill SA, Hobson B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 1983;19:271-5.
2. Folkman J. Tumor angiogensis: role in regulation of tumor growth. Symp Soc Dev Biol 1974;30:43-52.
3. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
4. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
5. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
6. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35.
7. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9:267-82.
8. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl 1996;27:S86-8.
9. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9.
10. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189-95.
11. Bilenker JH, Flaherty KT, Rosen M, et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005;11:1527-33.
12. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 2004;13:1171-82.
13. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and In vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999;81:1318-27.
14. Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001;21:93-102.
15. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060-9.
16. Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation oranti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001;49:443-50.
17. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998;42:899-903.
18. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001;60:155-61.
19. Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1018-24.
20. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000;20:229-33.
21. Horsman MR, Murata R, Breidahl T, et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000;476:311-23.
22. Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001;8:157-60.
23. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6.
24. Pedley RB, Hill SA, Boxer GM, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 2001;61:4716-22.
25. Pedley RB, El Emir E, Flynn AA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys 2002;54:1524-31.
26. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000;6:139-46.
27. Hill SA, Toze GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002;22:1453-8.
28. Hua J, Sheng Y, Pinney KG, et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 2003;23:1433-40.
29. Rojiani AM, Rojiani MV. Morphologic manifestations of vascular-disrupting agents in preclinical models. London: Wiley: 2006. p. 81-94.
30. Shi W, Horsman MR, Siemann DW. Combined modality approaches using vasculare-disrupting agents. Vascular-targeted therapies in oncology. London: Wiley: 2006. p. 123-36.
31. Denekamp J, Hobson B. Endothelial-cell proliferation in experimental tumours. Br J Cancer 1982;46:711-20.
32. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 1984;23:217-25.
33. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.